Ferring B.v.

Cara Therapeutics, Inc.

Kazimierz Wisniewski

Claudio Daniel Schteingart

Robert Felix Galyean

Guangcheng Jiang

Pierre Riviere

Jacek Stalewski

Javier Sueiras-Diaz

Regent Laporte

Sudarkodi Alagarsamy

Geoffrey S Harris

Anders Nilsson

Aleksandr K Rabinovich

Britta Siekmann

Pierre Jm Riviere

Piere J-m Riviere

Chia-Ping Chang

Mattias Malm

Pierre J-M Riviere

Sudar Alagarsamy

Claudio Schteingart

Robert Galyean

Javier J Sueiras-Diaz

Vasopressin-2 receptor agonists, pharmaceutical compositions thereof and methods for using the foregoing for treating diabetes insipidus, primary nocturnal enuresis, and nocturia.

Vasopressin-2 receptor agonists

This disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof: in which m, p, A, Ar, Ar, Ar, R, R, and Rare defined in the specification. The compounds of formula (I) can be used as CGRP antagonists and can be used to treat migraine.

CGRP antagonist peptides

Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of, e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites. 

V1a receptor agonists

The present invention relates to pharmaceutical compositions having improved stability.

Pharmaceutical composition

V1A receptor agonists

The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. 

Compounds

The present application relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. 

Peptidic vasopressin receptor agonists

The present invention relates to oxytocin receptor agonist compounds, pharmaceutical compositions comprising the same, use of such compounds for the manufacture of a medicament for treatment of inter alia, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, labor induction and maintenance, lactation induction and maintenance, postpartum hemorrhage, Post Traumatic Stress Disorder (PTSD), pain, anxiety and other conditions, as well as to methods for the treatment of such conditions, wherein such compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification: 

Oxytocin receptor agonists

Novel GLP-2 analogs with improved pharmacokinetic properties are described as well as their use in the treatment of disease.

Peptidic GLP-2 agonists

The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.

More efficient and/or economical methods for synthesizing heptapeptide alcohol analogs of oxytocin are provided along with novel intermediates which are useful in synthesizing such oxytocin analogs. Efficient and economical methods for synthesizing intermediates useful in synthesizing these oxytocin analogs are also provided.

Methods for making intermediates and oxytocin analogues

The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of pain and disorders related thereto as well as a method for treatment of pain and disorders related thereto, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. 

Growing community of inventors

San Diego, CA, United States of America

Kazimierz Wisniewski